[2]
Nanavaty, P.; Alvarez, M.S.; Michael, W. Lung cancer screening: Advantages, controversies, and applications. Univ Calgary, 2014, 21(1), 9-14.
[3]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics. CA Cancer J. Clin., 2018, 68(1), 7-30.
[6]
NCCN. NCCN Clinical Practice Guidelines in Oncology NSCLC (version 7.2015). 2015.
[8]
Nathan, A. Pennell, Maria E Arcila, David R Gandara. Howard west biomarker testing for patients with advanced non-small cell lung cancer: Real-world issues and tough choices. Am. Soc. Clin. Oncol. Educ. Book, 2019, 39, 531-542.
[9]
Brown, S.; Banfill, K.; Marianne, C. The evolving role of radiotherapy in non-small cell lung cancer. Br. J. Radiol., 2019, 92(1104)20190524
[10]
Jonna, S.; Subramaniam, D.S. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): An update. Discov. Med., 2019, 27(148), 167-170.
[11]
Reck, M.; Borghaei, H.; Kenneth, J.B. Nivolumab plus ipilimumab in non-small-cell lung cancer. N. Engl. J. Med., 2019, 15(19), 2287-2302.
[12]
Remark, R.; Becker, C.; Gomez, J.E. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am. J. Respir. Crit. Care Med., 2015, 191(4), 377-390.
[19]
Labib, Mahmoud Kelley, S.O. Circulating tumor cell profiling for precision oncology. 2021, 15(6), 1622-1646.
[21]
Vassiliki, A; Ji-Youn, H. Myung-Ju, A Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation- positive advanced non-small cell lung cancer. 2020, 126(2), 373-380.
[25]
Mohammed, T.; Mangeshkar, S.; Desai, A. HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma. J. Oncol. Pharm. Pract., 2021, 27(7), 1806-1809.
[26]
Fanotto, V.; Ongaro, E.; Karim, R.; Antonio, A.; Nicola, S.; Lorenzo, F.; Enrico, V.; Lorenzo, A.; Francesco, L.; Gerardo, R.; Francesco, G.; Roberto, B.; Mario, S.; Giovanna, D.M.; Francesca, V.N.; Gianpiero, F.; Giuseppe, A. HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7(42), 69060-69074.
[27]
Mirza, S.; Hadi, N.; Pervaiz, S.; Sultan, Z.K.; Sameer, A.M.; Tariq, A.; Nawwaf, A.H.; Fahim, V. Expression of HER-2/neu in oral squamous cell carcinoma. 2020, 21(5), 1465-1470.
[28]
Jain, P.; Goyal, S.; Chauhan, G.; Kaushik, M.; Shahajad, A.; Puja, S.; Anil, K.A. HER-2/neu over expression in gall bladder adenocarcinoma: A quest for potential therapeutic target. Indian J. Pathol. Microbiol., 2020, 63(2), 214-220.
[29]
Leonetti, A.; Sharma, S.; Minari, R.; Paola, P.; Elisa, G.; Marcello, T. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer, 2019, 121(9), 725-737.
[30]
Remon, J.; Steuer, C.E.; Ramalingam, S.S.; Felip, E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann. Oncol., 2018, 29(Suppl. 1), i20-i27.
[31]
Hsu, C.C.; Liao, B.C.; Liao, W.Y.; Markovets, A.; Stetson, D.; Thress, K.; Yang, J.C. Exon 16-skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell. Lung Cancer, 2020, 15(1), 50-61.
[32]
Sun, P. QU, Y.; Wang, Y.; Wang, J.; Wang, X.; Sheng, J. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer. J. Cancer, 2021, 12(13), 3900-3908.
[33]
Mok, T.S.; Wu, Y.L.; Ahn, M.J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.; Lee, C.K.; Sebastian, M.; Templeton, A.; Mann, H.; Marotti, M.; Ghiorghiu, S.; Papadimitrakopoulou, V.A. AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive. N. Engl. J. Med., 2017, 376(7), 629-640.
[34]
Papadimitrakopoulou, V.A.; Mok, T.S.; Han, J.Y.; Ahn, M.J.; Delmonte, A.; Ramalingam, S.S.; Kim, S.W.; Shepherd, F.A.; Laskin, J.; He, Y.; Akamatsu, H.; Theelen, W.S.M.E.; Su, W.C.; John, T.; Sebastian, M.; Mann, H.; Miranda, M.; Laus, G.; Rukazenkov, Y.; Wu, Y.L. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann. Oncol., 2020, 31(11), 1536-1544.
[36]
Ewer, M.S.; Tekumalla, S.H.; Walding, A.; Atuah, K.N. Cardiac safety of osimertinib: A review of data. J. Clin. Oncol., 2021, 39(4), 328-337.
[37]
Montemurro, F.; Delaloge, S.; Barrios, C.H.; Wuerstlein, R.; Anton, A.; Brain, E.; Hatschek, T.; Kelly, C.M.; Peña-Murillo, C.; Yilmaz, M.; Donica, M.; Ellis, P. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann. Oncol., 2020, 31(10), 1350-1358.
[38]
Nooreldeen, R.; Bach, H. Current and future development in lung cancer diagnosis. Int. J. Mol. Sci., 2021, 22(16), 8661.
[39]
Vasseur, A.; Kiavue, N.; Bidard, F.C.; Pierga, J.Y.; Cabel, L. Clinical utility of circulating tumor cells: An update. Mol. Oncol., 2021, 15(6), 1647-1666.
[41]
Tayoun, T.; Faugeroux, V.; Oulhen, M.; Aberlenc, A.; Pawlikowska, P.; Farace, F. CTC-derived models: A window into the seeding capacity of Circulating Tumor Cells (CTCs). Cells, 2019, 8(10), 1145.
[43]
Robichaux, J.P.; Elamin, Y.Y.; Tan, Z.; Carter, B.W.; Zhang, S.; Liu, S.; Li, S.; Chen, T.; Poteete, A.; Estrada-Bernal, A.; Le, A.T.; Truini, A.; Nilsson, M.B.; Sun, H.; Roarty, E.; Goldberg, S.B.; Brahmer, J.R.; Altan, M.; Lu, C.; Papadimitrakopoulou, V.; Politi, K.; Doebele, R.C.; Wong, K.K.; Heymach, J.V. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat. Med., 2018, 24(5), 638-646.